A first in human phase i study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 290-296

  Gallerani, Elisa ^a   Zucchetti, Massimo ^b   Brunelli, Dario ^b   Marangon, Elena ^b,c   Noberasco, Cristina ^d   Hess, Dagmar ^e   Delmonte, Angelo ^a   Martinelli, Giovanni ^d   Böhm, Steffen ^e   Driessen, Christopher ^e   De Braud, Filippo ^f   Marsoni, Silvia ^g   Cereda, Roberta ^h   Sala, Federica ^b   D'Incalci, Maurizio ^b   Sessa, Cristiana ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Southern Europe New Drug Organization SENDO   (Italy)

^h Ethical Oncology Science (EOS) SpA   (Italy)

Author keywords

Bortezomib analogue; Multiple myeloma; Phase I; Proteasome inhibitor

Indexed keywords

CARBOPLATIN; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PACLITAXEL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD CHEMISTRY; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL TUMOR; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; FEMALE; FEVER; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEURALGIA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN BIOPSY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 84872109533     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.009     Document Type: Article

References (12)

1. L.R. Dick, and P.E. Fleming Building on bortezomib: second generation proteasome inhibitors as anti-cancer therapy Drug Discov Today 15 2010 243 249
2. R. Piva, and B. Ruggeri Williams H et al CEP 18770: a novel, orally active proteasome inhibitor with a tumor selective pharmacologic profile competitive with bortezomib Blood 111 2008 2765 2775
3. G. Cavaletti, S. Jann, and A. Pace Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity J Peripher Nerv Syst 11 2006 135 141
4. D. Bouhassira, N. Attal, and H. Alchaar Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain 114 2005 29 36
5. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
6. B.G. Durie, J.L. Harousseau, and J.S. Miguel International uniform response criteria for multiple myeloma Leukemia 20 2006 1467 1473
7. F. Sala, E. Marangon, and R. Bagnati Development and validation of a high performance liquid chromatography tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study J Mass Spectrom 45 2010 1299 1305
8. E.S. Lightcap, T.A. McCormack, C.S. Pien, V. Chau, J. Adams, and P.J. Elliott Proteasome inhibition measurements: clinical application Clin Chem 46 2000 673 683
9. D. Levêque, M.C. Monteiro Carvalho, and F. Maloiesel Review. Clinical pharmacokinetics of bortezomib In vivo 21 2007 273 278
10. D.E. Reece, D. Sullivan, and S. Lonial Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma Cancer Chemother Pharmacol 67 2011 57 67
11. O.A. O'Connor, A.K. Stewart, and M. Vallone A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 2009 7085 7091
12. S.D. Demo, C.J. Kirk, and M.A. Aujay Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 2007 6383 6391